Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

Item

http://www.wikidata.org/entity/Q41859441

Q41859441

about

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series)Inotropes do not increase mortality in advanced heart failure Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.Chronic heart failure: current evidence, challenges to therapy, and future directions.Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?A review of current therapies used in the treatment of congestive heart failure.Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.New medical therapies for heart failure.Current Approach to Decongestive Therapy in Acute Heart Failure.Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting.Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes.How robust are clinical trials in heart failure?Oral Enoximone as an Alternative to Protracted Intravenous Medication in Severe Pediatric Myocardial Failure.Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation.Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.Cardiotonic modulation in heart failure: insights from traditional Chinese medicine Progress or lack of progress in hospitalized heart failure.Extended release oral milrinone as an adjunct to heart failure therapy.A pathophysiological role of PDE3 in allergic airway inflammation.Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis.

P2860

Q24645066-A545C181-F761-4A8F-9787-F684A5CAADB7 Q26741100-3720C9B5-F32B-4AA7-AD1B-192E29D870C8 Q26781681-673B4940-6E38-4B25-9066-8CE78A2CAB51 Q33685748-01AE9EB4-B66E-4513-9CD7-4065954D1E4D Q36848480-268E3D23-36F3-4498-A183-3B64E248B4EB Q37858515-1A5C3039-157A-42B9-AA7D-02346CCEBE14 Q37880858-B60C75D3-8DD2-49FC-B778-8C79F7F257D4 Q38061473-6FD5581D-3EB6-4C6E-99FD-EA06B796D22C Q38131789-597E3A5A-2EF5-4BE0-BDBD-078E09FD6376 Q38173852-F90A1BAE-42F3-48AC-A50B-83F632D5C253 Q38594785-BE969469-A6B3-463A-BCFC-E5153E761402 Q38612606-F90FDC34-C1C8-412A-B7E9-3A6ED403D392 Q38815663-06FBB0E6-9CA9-4E9B-AB4C-A37EFCC951E9 Q38992600-0C551E04-CDD8-4F16-9740-2E9DA20C04BE Q39136145-D3E3D838-1881-44DF-838E-785DDD2AA989 Q39289642-66743D6D-E026-404A-92F0-8D236CF17163 Q40625826-C3260B51-6BFE-4D62-BEB8-39A58C1EEA37 Q41302280-80BB030D-7C96-4D35-A9A8-89AF13176C26 Q41686228-D3AF7095-FF8E-452A-9C6D-C94EF00ABEEC Q42576790-726F4A34-5CE6-4937-8A32-61738E25E51A Q45904891-04FFD995-8052-4F1C-B416-6FA737AE07FD Q48283260-83B308C0-656A-4D6A-8ADD-975E65ABF217 Q49030605-81939FB5-D22B-406D-83BA-C58FFC4382FA Q51756509-A19CE933-DEC0-4C6C-8D61-BBFC94B8817C

P2860

Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

Item

http://www.wikidata.org/entity/Q41859441

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Effects of low-dose oral enoxi ...... arallel group ESSENTIAL trials

@en

type

Item

label

Effects of low-dose oral enoxi ...... arallel group ESSENTIAL trials

@en

prefLabel

Effects of low-dose oral enoxi ...... arallel group ESSENTIAL trials

@en

P1476

Effects of low-dose oral enoxi ...... arallel group ESSENTIAL trials

@en

P2093

Brian Wiens

http://www.w3.org/2001/XMLSchema#string

David DeMets

http://www.w3.org/2001/XMLSchema#string

ESSENTIAL Investigators

http://www.w3.org/2001/XMLSchema#string

Ellen Roecker

http://www.w3.org/2001/XMLSchema#string

Eric Eichhorn

http://www.w3.org/2001/XMLSchema#string

Jennifer Linseman

http://www.w3.org/2001/XMLSchema#string

Jennifer Stewart

http://www.w3.org/2001/XMLSchema#string

Michael Böhm

http://www.w3.org/2001/XMLSchema#string

Michael Gerber

http://www.w3.org/2001/XMLSchema#string

Michael R Bristow

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators.

The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure

Inotropes and beta-blockers: is there a need for new guidelines?

Mechanisms and models in heart failure: the biomechanical model and beyond.

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.

Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review.

Are hemodynamic goals viable in tailoring heart failure therapy? Hemodynamic goals are relevant.

Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.

Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.

P304

3015-3026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHP338

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26761115

http://www.w3.org/2001/XMLSchema#string

P698

19700774

http://www.w3.org/2001/XMLSchema#string

P921

heart failure

P932

2792716

http://www.w3.org/2001/XMLSchema#string

Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

about

P2860

P2860

Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932